HENLIUS Shares Rise on Canadian Commercial Launch of Denosumab Products

Stock News06-24

Shares of HENLIUS (02696) climbed nearly 4% in Hong Kong trading. At the time of writing, the stock was up 3.98% to HK$65.05, with a turnover of approximately HK$10.51 million.

The catalyst for the move was a recent announcement. On June 23rd, the company and its partner Organon Canada declared that the denosumab injection BILDYOS® (60 mg/mL) and the denosumab injection TUZEMTY® (120 mg/1.7 mL) have officially been commercially launched in Canada. These products cover all Canadian-approved indications for the originator drugs PROLIA and XGEVA.

Denosumab is indicated for multiple conditions, functioning by enhancing bone strength to treat osteoporosis and manage tumor-related bone events. The launch of BILDYOS® in Canada is reported to broaden treatment options for patients in the region. It is also expected to help reduce healthcare costs by improving the accessibility of biosimilar medicines.

These two new products further augment Organon's expanding biosimilar portfolio in Canada. This portfolio now spans five major therapeutic areas, including oncology, and features several products that have been on the market for over nine years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108962855?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108962855","market":"hk","top_or_hot":-1,"title":"HENLIUS Shares Rise on Canadian Commercial Launch of Denosumab Products","media":"Stock News","content":"<p>Shares of <b>HENLIUS</b> (<b>02696</b>) climbed nearly 4% in Hong Kong trading. At the time of writing, the stock was up 3.98% to HK$65.05, with a turnover of approximately HK$10.51 million.<br><br>\nThe catalyst for the move was a recent announcement. On June 23rd, the company and its partner Organon Canada declared that the denosumab injection BILDYOS® (60 mg/mL) and the denosumab injection TUZEMTY® (120 mg/1.7 mL) have officially been commercially launched in Canada. These products cover all Canadian-approved indications for the originator drugs PROLIA and XGEVA.<br><br>\nDenosumab is indicated for multiple conditions, functioning by enhancing bone strength to treat osteoporosis and manage tumor-related bone events. The launch of BILDYOS® in Canada is reported to broaden treatment options for patients in the region. It is also expected to help reduce healthcare costs by improving the accessibility of biosimilar medicines.<br><br>\nThese two new products further augment Organon's expanding biosimilar portfolio in Canada. This portfolio now spans five major therapeutic areas, including oncology, and features several products that have been on the market for over nine years.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS Shares Rise on Canadian Commercial Launch of Denosumab Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS Shares Rise on Canadian Commercial Launch of Denosumab Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-24 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>HENLIUS</b> (<b>02696</b>) climbed nearly 4% in Hong Kong trading. At the time of writing, the stock was up 3.98% to HK$65.05, with a turnover of approximately HK$10.51 million.<br><br>\nThe catalyst for the move was a recent announcement. On June 23rd, the company and its partner Organon Canada declared that the denosumab injection BILDYOS® (60 mg/mL) and the denosumab injection TUZEMTY® (120 mg/1.7 mL) have officially been commercially launched in Canada. These products cover all Canadian-approved indications for the originator drugs PROLIA and XGEVA.<br><br>\nDenosumab is indicated for multiple conditions, functioning by enhancing bone strength to treat osteoporosis and manage tumor-related bone events. The launch of BILDYOS® in Canada is reported to broaden treatment options for patients in the region. It is also expected to help reduce healthcare costs by improving the accessibility of biosimilar medicines.<br><br>\nThese two new products further augment Organon's expanding biosimilar portfolio in Canada. This portfolio now spans five major therapeutic areas, including oncology, and features several products that have been on the market for over nine years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1108962855","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108962855","pubTimestamp":1782268101,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of HENLIUS (02696) climbed nearly 4% in Hong Kong trading. At the time of writing, the stock was up 3.98% to HK$65.05, with a turnover of approximately HK$10.51 million. The catalyst for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","IPOS":"Renaissance International IPO ETF","BK4588":"碎股","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK4585":"ETF&股票定投概念","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","02696":"复宏汉霖"},"translate_title":"复宏汉霖股价因地舒单抗产品在加拿大商业上市而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"VXUS":1,"02696":1},"content_text":"Shares of HENLIUS (02696) climbed nearly 4% in Hong Kong trading. At the time of writing, the stock was up 3.98% to HK$65.05, with a turnover of approximately HK$10.51 million.\nThe catalyst for the move was a recent announcement. On June 23rd, the company and its partner Organon Canada declared that the denosumab injection BILDYOS® (60 mg/mL) and the denosumab injection TUZEMTY® (120 mg/1.7 mL) have officially been commercially launched in Canada. These products cover all Canadian-approved indications for the originator drugs PROLIA and XGEVA.\nDenosumab is indicated for multiple conditions, functioning by enhancing bone strength to treat osteoporosis and manage tumor-related bone events. The launch of BILDYOS® in Canada is reported to broaden treatment options for patients in the region. It is also expected to help reduce healthcare costs by improving the accessibility of biosimilar medicines.\nThese two new products further augment Organon's expanding biosimilar portfolio in Canada. This portfolio now spans five major therapeutic areas, including oncology, and features several products that have been on the market for over nine years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108962855","isCrawlerRequest":true}